Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Landmark: Sanofi...

    Landmark: Sanofi announces to reduce price of TB drug Rifapentine by 70 percent

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-01T15:29:45+05:30  |  Updated On 17 Aug 2021 11:21 AM IST
    Scale-up of affordable Rifapentine stands to benefit over a million people in India alone, where more people suffer from TB than anywhere else in the world.

    HYDERABAD: In a landmark development, global biopharmaceutical company Sanofi will lower the price of Rifapentine, a critically important drug used to prevent tuberculosis (TB), as part of the agreement with Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria, an official release said on Thursday.


    The announcement came at the 50 th Union World Conference on Lung Health 2019 being held here.


    Scale-up of affordable Rifapentine stands to benefit over a million people in India alone, where more people suffer from TB than anywhere else in the world.


    The Indian government has set ambitious targets to eliminate TB by 2025.


    Sanofi's rifapentine medicine, Priftin, is already on the list of WHO prequalified products, registered in 11 countries and is in the process of being registered in many other countries.


    "Sanofi is very pleased to have concluded this innovative agreement. We believe that this sustainable commercial approach will widen access to the new standard of care for latent tuberculosis infection. Through this Global Health initiative, Sanofi remains at the forefront of the fight against Tuberculosis," Jon Fairest, Vice President, External Affairs-Africa and Eurasia Middle East, Sanofi, said.


    The volume-based agreement will discount the price of a three-month treatment course of Rifapentine by nearly 70 per cent, from approximately USD45 to USD15 (ex works) in the public sectors of 100 low and middle-income countries burdened by TB and TB/HIV coinfection, the release said.


    "Effective TB prevention will be a game-changer in the global fight to eliminate one of the major killer diseases. This lifesaving drug has, until now, been completely unaffordable in developing countries. This agreement will help transform political commitment to tangible action," Unitaid's Executive Director Lelio Marmora said.


    Read Also: Sanofi pulls popular heartburn drug Zantac in US, Canada


    The deal will bolster efforts to treat latent TB infection - currently estimated to affect 1.7 billion people worldwide - by broadening access to better preventive therapy, the release said.


    A quarter of the world's population is infected with latent TB they have no symptoms, are not contagious and most do not know they are infected.


    Without treatment, 5 to 10 per cent of these people 85 million to 170 million people globally will develop active TB, the form which makes people sick and can be transmitted from person to person.


    HIV infection makes people up to 37 times more likely to fall ill with the active disease. Close to 1.5 million people die of TB every year.


    Read Also: Sanofi opens digital biologics manufacturing facility in US

    AIDSHIV infectionJon FairestLelio Marmorapharmapharma companypharma newsRifapentineSanofiTBTB drugTuberculosistuberculosis infection
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok